EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access · CC BY-NC 4.0

Guselkumab for the treatment of patients with moderate‐to‐severe hidradenitis suppurativa: A phase 2 randomized study

Alexa B Kimball iD, Maurizio Podda, Afsaneh Alavi iD, Megan Miller, Yaung-Kaung Shen, Shu Li, Yan Xu, Chenglong Han, Steven Fakharzadeh, Ya-Wen Yang, Samuel DePrimo, Ernesto Munoz und 3 weitere

Journal of the European Academy of Dermatology and Venereology · 2023

DOI: 10.1111/jdv.19252 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von Alexa B Kimball und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Psoriasis. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Janssen Global Services, LLC, Janssen Research and Development, LLC, Janssen Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that causes substantial physical, emotional and psychological burdens. Guselkumab, a monoclonal antibody that binds to the p19 subunit of interleukin‐23, has demonstrated high levels of efficacy in the treatment of inflammatory diseases, including psoriasis and psoriatic arthritis.

Objective

To evaluate the effect of guselkumab on the treatment of HS, a phase 2, multicentre, randomized, placebo‐controlled, double‐blind, proof‐of‐concept study was conducted.

Methods

Patients ≥18 years of age with moderate‐to‐severe HS for ≥1 year were randomized to (1) guselkumab 200 mg by subcutaneous (SC) injection every 4 weeks (q4w) through Week 36 (guselkumab SC); (2) guselkumab 1200 mg intravenously (IV) q4w for 12 weeks, then switched to guselkumab 200 mg SC q4w from Weeks 12 through 36 (guselkumab IV); or (3) placebo for 12 weeks, with re‐randomization to guselkumab 200 mg SC q4w at Weeks 16 through 36 (placebo → guselkumab 200 mg) or guselkumab 100 mg SC at Weeks 16, 20, 28 and 36 and placebo at Weeks 24 and 32 (placebo → guselkumab 100 mg). End points included HS clinical response (HiSCR) and patient‐reported outcomes.

Results

Although guselkumab SC or guselkumab IV resulted in numerically higher HiSCR versus placebo at Week 16 (50.8%, 45.0%, 38.7%, respectively), statistical significance was not achieved. Numerically greater improvements in patient‐reported outcomes were also observed for guselkumab SC and guselkumab IV versus placebo at Week 16. Through Week 40, no clear differences to suggest a dose response were observed for HiSCR and patient‐reported outcomes.

Conclusions

Despite modest improvements, the primary end point was not met and the overall findings do not support the efficacy of guselkumab in the treatment of HS. Clinicaltrials.gov : NCT 03628924.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaPsoriasisHumansInfant, NewbornTreatment OutcomeSeverity of Illness IndexAntibodies, Monoclonal, HumanizedDouble-Blind Method

Substanzen

guselkumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Dermatology, Medical Center Klinikum Darmstadt, Teaching Hospital Goethe-University Frankfurt, Darmstadt, Germany.
  • Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA.
  • Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
  • Patient-Reported Outcomes, Janssen Global Services, LLC, Malvern, Pennsylvania, USA.
  • Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA.

ORCID-Profile: Alexa B Kimball, Afsaneh Alavi, Yanqing Chen, Thierry Passeron, Kim Papp

Förderung

  • Janssen Global Services, LLC
  • Janssen Research and Development, LLC
  • Janssen Research and Development

Zitieren

APA

Kimball, A. B., Podda, M., Alavi, A., Miller, M., Shen, Y. K., Li, S., Xu, Y., Han, C., Fakharzadeh, S., Yang, Y. W., DePrimo, S., Munoz, E., Chen, Y., Passeron, T., & Papp, K. (2023). Guselkumab for the treatment of patients with moderate‐to‐severe hidradenitis suppurativa: A phase 2 randomized study. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19252

Vancouver

Kimball AB, Podda M, Alavi A, Miller M, Shen YK, Li S, et al. Guselkumab for the treatment of patients with moderate‐to‐severe hidradenitis suppurativa: A phase 2 randomized study. Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.19252

BibTeX
@article{Kimball2023,
  author = {Kimball, Alexa B and Podda, Maurizio and Alavi, Afsaneh and Miller, Megan and Shen, Yaung-Kaung and Li, Shu and Xu, Yan and Han, Chenglong and Fakharzadeh, Steven and Yang, Ya-Wen and DePrimo, Samuel and Munoz, Ernesto and Chen, Yanqing and Passeron, Thierry and Papp, Kim},
  title = {Guselkumab for the treatment of patients with moderate‐to‐severe hidradenitis suppurativa: A phase 2 randomized study},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2023},
  doi = {10.1111/jdv.19252}
}
Kostenlos starten →